Status:
UNKNOWN
Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria
Lead Sponsor:
Medical University Innsbruck
Conditions:
Recurrent Ovarian Carcinoma
Eligibility:
FEMALE
18-99 years
Brief Summary
Various treatment options exist for patients with platinum-sensitive relapsed epithelial ovarian cancer (ROC). The register will provide an overview of chosen treatments including the reasons, why th...
Detailed Description
Patients at their first platinum-sensitive ROC will be invited to participate in the register. These are all patients with recurrent disease 6 or more months after the last cycle of platinum containi...
Eligibility Criteria
Inclusion
- Women aged 18 years or older
- Presence of first platinum-sensitive ROC (ovarian, peritoneal and/or fallopian tube cancer)
- Must have received at least 4 cycles of chemotherapy during primary therapy
- At time of inclusion a treatment for ROC must be planned
- Patients must not have more than 1 prior line of chemotherapy
- Signed informed consent
Exclusion
- No knowledge of spoken and written German
- Signed informed consent is not given
Key Trial Info
Start Date :
August 9 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04369352
Start Date
August 9 2018
End Date
August 1 2025
Last Update
March 28 2023
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Graz
Graz, Austria
2
Medical University Innsbruck
Innsbruck, Austria
3
Bezirkskrankenhaus Kufstein
Kufstein, Austria
4
LKH Hochsteiermark
Leoben, Austria